共查询到18条相似文献,搜索用时 609 毫秒
1.
替尼泊甙和卡铂联合化疗晚期肺癌近期疗效评价钟义罗克枢邵文君关键词肺肿瘤替尼泊甙卡铂联合化疗中图号R734.2R730.53表3VM-26、CBP化疗方案毒副反应(例,%)自194年1月至1995年4月,我院采用替尼泊甙(鬼臼噻吩甙、Teniposid... 相似文献
2.
以替尼泊甙为主的化疗方案相伴放疗治疗小细胞肺癌 总被引:2,自引:0,他引:2
目的探讨替尼泊甙(VM-26)为主的化疗方案相伴放疗治疗小细胞肺癌的临床疗效。方法53例小细胞肺癌中,48例选用VM-26+顺铂(DDP)方案,VM-26每天60mg/m2,DDP每天25mg/m2,连用3天为一个疗程;另5例用卡铂取代DDP,500mg静脉滴注,1天完成。除第1个与第2个疗程化疗间隔40天左右外,以后每4周重复1个疗程,共5个疗程。在第1个疗程化疗后1~4天内开始放射治疗。对局限期和广泛期患者分别照射不同的剂量和部位。结果局限期患者近期疗效为97.8%[完全缓解(CR)为53.3%,部分缓解(PR)为44.8%],1年和2年生存率分别为77.1%(27/35)和44%(11/25),中位生存期大于18个月。广泛期患者近期疗效为75%(CR25%),一年生存率为37.5%(3/8),中位生存期大于11个月。结论以VM-26为主的化疗方案相伴放疗是治疗小细胞肺癌的有效方案,可提高肿瘤的局部控制率。 相似文献
3.
4.
目的评价替尼泊甙-司莫司汀(VM-26—MeCCNU)联合方案治疗颅内恶性肿瘤的效果。方法经病理确诊的颅内恶性肿瘤60例,随机分为两组。治疗组30例,采用VM-26—MeCCNU方案;对照组30例,采用依托泊甙-司莫司汀(VP-16—MeCCNU)方案。5天为一个周期,每个周期间隔4周,连续4个周期。观察指标包括临床症状和体征、头颅CT或MRI检查。随访时间4~12个月以上。结果治疗组与对照组的总有效率分别为63.3%和36.6%(P<0.05)。结论VM-26—MeCCNU序列治疗颅内恶性肿瘤是一种安全有效的化疗方案。 相似文献
5.
6.
采用ADMV(ADM+DDP+MMP+MMC+VP-16)方案联合化疗,对62例中晚期非小细胞肺癌近期疗效观察,CR2例,PR18例,NR32例,PD10例, 效率(CR+PR)32.26%)20/62),化疗毒副反庆主要是消化道反 (59.68%)及骨髓抑制(白细胞下降占61.29%). 相似文献
7.
VM-26、DDP治疗晚期肺癌17例,总缓解率52.9%,其中小细胞肺癌的缓解率83.3%,非小细胞肺癌36.3%。初治病人的疗效明显高于复治病人,增加疗程能提高缓解率,由于VM-26能透过血脑屏障,对肺癌脑转移的病人疗效较好。本方案疗效好,毒副反应低,值得进一步应用观察。 相似文献
8.
鬼臼乙叉甙软胶囊治疗恶性肿瘤的临床验证报告 总被引:4,自引:0,他引:4
1993年6月~1994年4月,作者组织了全国5家医院,对南京药物研究所和江苏连云港制药厂研制的口服鬼臼乙叉甙(VP-16)软胶囊进行临床验证。全组可评价疗效者110例,VP-16单药口服治疗50例,口服VP-16联合治疗60例,其它相应治疗对照45例。结果表明,口服单药有效率在小细胞肺癌为50%(9/18),恶性淋巴瘤为83.3%(15/18),卵巢癌为1/6,胃癌为0/8。联合用药治疗组与对照组的有效率:小细胞肺瘤为57.1%及55.6%,恶性淋巴瘤为95%及87.5%,胃癌为1/5及0/2.鬼臼乙叉甙口服胶囊毒副反应轻微,病人耐受性好,单药或联合用药治疗小细胞肺癌、恶性淋巴瘤、卵巢癌有较好疗效,可进一步扩大使用。 相似文献
9.
丝裂霉素,长春花碱酰胺,顺铂联合治疗晚期非小细胞肺癌108例 总被引:34,自引:0,他引:34
目的 观察丝裂霉素(MMC)、长春花碱酰胺(VDS)、顺铂(DDP)联合化疗治疗晚期非小细胞肺癌的疗效。方法 治疗非小细胞肺癌患者108例。病理类型以腺癌(74例)和鳞癌(23例)为主。初治78例,复治者有效率16.7%(P=0.0169)。鳞癌有效率30.4%,腺癌有效率32.4%。淋巴结转移、肺原发肿瘤、肺内转移、肝转移和骨转移的有效率依次为43.1%、37.6%、32.4%、25.0%和0。 相似文献
10.
11.
M Fukuoka N Masuda K Furuse S Negoro M Takada K Matsui N Takifuji S Kudoh M Kawahara M Ogawara 《Journal of clinical oncology》1991,9(4):606-613
Patients with inoperable non-small-cell lung cancer (NSCLC) were randomly assigned to receive one of three dosage regimens: (1) vindesine and cisplatin (VP); (2) mitomycin, vindesine, and cisplatin (MVP); or (3) etoposide and cisplatin alternating with vindesine and mitomycin (EP/VM). In 199 assessable patients, the response rates were VP, 33%; MVP, 43%; and EP/VM, 19%. The addition of mitomycin to the VP regimen did not significantly improve the response rate. The response rate was significantly lower with the EP/VM regimen than with the MVP regimen (P less than .01). The median survival times were VP, 50 weeks; MVP, 42 weeks; and EP/VM, 40 weeks. These differences were not significant. Grade III or IV thrombocytopenia was significantly greater (P less than .01) in MVP patients (22%) than in the VP (5%). Other toxicities were similar in the three groups. Analyses of prognostic factors showed that treatment with MVP, sex, and histologic classification (squamous cell carcinoma) were predictive of improved response. Important factors for improved survival, according to the Cox regression analysis, were the stage of disease, performance status, sex, weight loss before diagnosis, and hemoglobin concentration. 相似文献
12.
Objective:The aim of the study was to evaluate the responses and toxicities of liposome encapsulated paclitaxel (LEP) plus cisplatin (DDP) (LP regimen) and paclitaxel (TAX) plus DDP (TP regimen) in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: A total of 89 cases with advanced NSCLC was randomized into two groups: the LP group (57 patients) and the TP group (32 patients). The responses, toxicities and survivals of the two groups were compared. Results: The response rates were 40.00%... 相似文献
13.
VP方案与MVP方案治疗非小细胞肺癌的疗效比较 总被引:5,自引:0,他引:5
目的;比较VP方案与MVP方案对非小细胞肺癌(NSCLC)的治疗效果。方法:78例患者分别用VP(VDS+DDP)方案和MVP(MMC+VP)方案治疗。结果:VP组和MVP组有效分别为45.7%和47.2%,两者无显著怀差异。分析诸因素对疗效的影响发现,病期早较病期晚疗效好。生活质量评估Kamofsky评分一升高为71.4%,MVP组为69.4%,两组无显著性差异。骨髓抑制为限制性毒性,白细胞下降 相似文献
14.
目的:观察健择(gemcitabine,GEM)/顺铂(DDP)每周给药方案治疗晚期非小细胞肺癌(nonsmallcelllungcancel,NSCLC)的近期疗效和毒性反应。方法:37例晚期NSCLC,分别于d1、d8和d15联合应用GEM(1000mg/m2)和DDP(25mg/m2),28d为1个周期。治疗至少2个周期评价疗效。结果:36例可评价疗效,所有患者无CR,PR12例,NC15例,PD9例,总有效率为33.3%(12/36)。37例可评价毒性,3、4度粒细胞减少、血小板减少分别为13.5%(5/37)和16.2%(6/37)。结论:GEM/DDP每周给药方案疗效与其他GEM/DDP联合方案疗效相仿,但毒性反应明显低于其他方案,可用于老年患者或一般状况较差患者的治疗。 相似文献
15.
目的比较L—OHP与NP方案治疗晚期NSCLC的近期疗效和毒副反应。方法将64例经病理检查确诊的NSCLC患者随机分为2组:治疗组32例,NVB25mg/m^2静脉点滴,第1、8天,L—OHP130mg/m^2静脉点滴2h,第2天,每21天为1个周期;对照组32例:NVB25mg/m^2静脉点滴,第1、8天,顺铂70mg/m^2分3天静脉滴注,从第2天开始,每21天为1个周期。对两组的总反应率和毒副反应作回顾性分析。结果治疗组与对照组的总反应率分别为62.5%(20/32)和34.4%(11/32),有显著性差异(χ^2=4.0,P〈0.05);治疗组有2例CR患者;两组主要毒副反应为血液和神经毒性。结论L—OHP+NVB方案治疗晚期NSCLC近期疗效较NP方案好,毒副反应均能耐受。 相似文献
16.
Overexpression of Multidrug Resistance Protein Gene in Human Cancer Cell Lines Selected for Drug Resistance to Epipodophyllotoxins 总被引:1,自引:3,他引:1
Koji Koike Tatsuya Abe Terumasa Hisano Takeshi Kubo Morimasa Wada Kimitoshi Kohno Michihiko Kuwano 《Cancer science》1996,87(7):765-772
Overexpression of either the multidrug resistance 1 (MDR1) gene or multidrug resistance protein (MRP) gene is involved in acquisition of multidrug-resistant phenotypes in human cancer cells. In this study we examined whether selection for resistance to the epipodophyllotoxins, etoposide/teniposide (VP16/VM26), could induce overexpression of MDR1 or MRP. We have previously isolated two VP16/VM26-resistant KB cell lines. Two VP16/VM26-resistant KB cell lines, KB/VM-1 and KB/VM-4, which were selected by stepwise exposure to VM26 had decreased accumulation of [3 H]VP16 and increased levels of MRP, but no apparent expression of MDR1 gene was observed. Another VP16/VM26-resistant KB cell line, KB/VP-4, which was further isolated from a VP16-resistant KB cell line, KB/VP-2, had decreased accumulation of [3 H]VP16 and showed overexpression of MRP gene, but not that of MDR1 gene. We also isolated a VP16-resistant cell line, IN157/VP-1, from a human glioma cell line IN157. IN157/VP-1 cells showed decreased accumulation of [3 H]VP16 and overexpression of MRP gene, but not of MDR1. These findings suggest that selection for resistance to VP16/VM26, preferentially induces overexpression of MRP gene. 相似文献
17.
Cisplatin-based combination chemotherapy for elderly patients with non-small-cell lung cancer 总被引:5,自引:0,他引:5
Kaoru Kubota Kiyoyuki Furuse Masaaki Kawahara Nagahisa Kodama Mitsumasa Ogawara Minoru Takada Noriyuki Masuda Shunichi Negoro Kaoru Matsui Nobuhide Takifuji Shinzou Kudoh Yoko Kusunoki Masahiro Fukuoka 《Cancer chemotherapy and pharmacology》1997,40(6):469-474
Purpose: To compare the response rates, toxicities and survival durations of elderly patients (70 years of age or more) with those
of younger patients ( less than 70 years of age) with non-small-cell lung cancer (NSCLC) treated with cisplatin-based chemotherapy.
Patients and methods: We analyzed retrospectively the data of 203 assessable patients entered on a prospective randomized trial of cisplatin-based
combination chemotherapy. Chemotherapy consisted of three dosage regimens: (1) vindesine and cisplatin (VP); (2) mitomycin,
vindesine and cisplatin (MVP); or (3) etoposide and cisplatin alternating with vindesine and mitomycin (EP/VM). Results: A greater proportion of elderly patients had localized disease and more squamous cell carcinoma than non-elderly patients.
The overall response rates were 44% in the elderly group and 28% in the non-elderly group. In the EP/VM arm, the response
rate was significantly better in the elderly group than in the non-elderly group. The frequency of grade 4 leukocytopenia
in the MVP and EP/VM arms in the elderly group was significantly greater than in the non-elderly group (P < 0.05). No differences were found in nonhematological toxicities between the two groups. There was no difference in overall
survival between the groups. Conclusion: Elderly patients treated with mitomycin-containing regimens have higher hematologic toxicities than younger patients. The
results of this study are consistent with the previously reported pharmaco logic data on mitomycin suggesting altered pharmacokinetics
in elderly patients. The improved response rate in the elderly patients was probably because more elderly patients had earlier
disease, squamous cell carcinoma and better performance status. Cisplatin-based chemotherapy was tolerable for most elderly
NSCLC patients with good performance status.
Received: 30 October 1996 / Accepted: 20 March 1997 相似文献